Vaccines against bacterial meningitis.
Meningitis remains an important cause of morbidity and mortality among children >5 years of age and is especially prevalent in developing countries. Effective routine immunization against Hib, pneumococcus and serogroupC meningococcus has had a significant impact on both invasive disease and carriage caused by these encapsulated bacteria. The major challenge in prevention of meningitis remains the delivery of vaccines worldwide, especially to resource-poor regions with the greatest disease burden.
Segal
S
S
Department of Paediatrics, University of Oxford, Level 4, John Radcliffe Hospital, Oxford OX3 9DU, UK. Shelley.segal@paediatrics.oxford.ac.uk
Pollard
A J
AJ
D001426:Bacterial Proteins; D001428:Bacterial Vaccines / Q000627:therapeutic use*; D018073:Haemophilus Vaccines / Q000627:therapeutic use; D006801:Humans; D016920:Meningitis, Bacterial / Q000517:prevention & control*; D008583:Meningitis, Haemophilus / Q000517:prevention & control; D008585:Meningitis, Meningococcal / Q000517:prevention & control; D022401:Meningococcal Vaccines / Q000627:therapeutic use; D011008:Pneumococcal Infections / Q000517:prevention & control; D022242:Pneumococcal Vaccines / Q000627:therapeutic use; D013292:Streptococcus agalactiae / Q000276:immunology; D014376:Tuberculosis / Q000517:prevention & control; D032581:Tuberculosis Vaccines / Q000627:therapeutic use
D001426:Bacterial Proteins; D001428:Bacterial Vaccines; D018073:Haemophilus Vaccines; D022401:Meningococcal Vaccines; D022242:Pneumococcal Vaccines; D032581:Tuberculosis Vaccines